Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Wockhardt's share price for the quarter that ended in Jun. 2026 was ₹1942. Wockhardt's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 162 Mil. Therefore, Wockhardt's market cap for the quarter that ended in Jun. 2026 was ₹315,559 Mil.
Wockhardt's quarterly market cap
declined
from Dec. 2025 (₹234,947 Mil) to Mar. 2026 (₹191,294 Mil) but then
increased
from Mar. 2026 (₹191,294 Mil) to Jun. 2026 (₹315,559 Mil).
Wockhardt's annual market cap
increased
from Mar. 2024 (₹89,517 Mil) to Mar. 2025 (₹231,339 Mil) but then
declined
from Mar. 2025 (₹231,339 Mil) to Mar. 2026 (₹191,294 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Wockhardt's Enterprise Value for Today is ₹324,976 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Wockhardt Market Cap Related Terms
Wockhardt Market Cap Historical Data
* Premium members only.
The historical data trend for Wockhardt's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wockhardt's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wockhardt Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wockhardt's Market Cap distribution charts can be found below:
* The bar in red indicates where Wockhardt's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Wockhardt's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wockhardt (BOM:532300) has a Market Cap of ₹305,526 Mil as of Aug. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Wockhardt and its competitors. According to the industry distribution chart, Wockhardt ranks #111 out of 1021 companies in the Drug Manufacturers industry, placing it in the top 10.9%.
Is Wockhardt's Market Cap too high?
Wockhardt's current Market Cap is ₹305,526 Mil. Based on the distribution chart, Wockhardt ranks #111 out of 1021 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Wockhardt has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wockhardt's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wockhardt ranks #111 out of 1021 companies for Market Cap. This places Wockhardt in the top 11% of its industry — outperforming the majority of peers. The industry median Market Cap is 233.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 233.34, based on 1,021 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Wockhardt and its competitors. For the Drug Manufacturers industry, the median Market Cap is 233.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wockhardt's current Market Cap is ₹305,526 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wockhardt stock overvalued right now?
Based on GuruFocus' analysis, Wockhardt (BOM:532300) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,465.10, compared to a current price of ₹1,880.25 — trading 28.3% above its estimated fair value. The current Market Cap is ₹305,526 Mil. Wockhardt's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Wockhardt (BOM:532300), the current Market Cap is ₹305,526 Mil as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wockhardt (BOM:532300) Overvalued in 2026?
Based on GuruFocus' analysis, Wockhardt stock appears to be overvalued.
The current stock price of ₹1,880.25 is trading 28.3% above its estimated GF Value™ of ₹1,465.10.
GuruFocus considers Wockhardt to be Modestly Overvalued.
Key valuation signals for BOM:532300:
Market Cap: ₹305,526 Mil
GF Value™: ₹1,465.10 vs. price of ₹1,880.25 (28.3% above fair value)
No single metric tells the full story. See the BOM:532300 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The group is involved in new drug discovery, contract manufacturing, API, vaccines, and branded pharmaceuticals business. In addition, it operates a chain of super-specialty hospitals. Its novel antibiotic platform has various assets, such as Zaynich (WCK 5222); Miqnaf (Nafithromycin), a macrolide-class respiratory antibiotic; Ertapenem-Zidebactam (WCK 6777); Foviscu (WCK 2482), an antibiotic for Gram-negative infections; and Odrate (WCK 6777), among others. The group is mainly engaged in the pharmaceutical business, which is considered its only reportable business segment. Geographically, it generates maximum revenue from Europe, followed by India, the USA, and the Rest of the world.
55GF Score
Get the complete analysis for BOM:532300
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532300 has been successfully added to your 
